We noticed you are browsing from outside the United States of America (USA)

The information presented on this website is intended for healthcare professionals, patients, and caregivers located in the USA. To view information intended for users located outside of the USA, please visit our international website, www.rochefoundationmedicine.com. For biopharma partner information, please continue to the US Site.

Continue browsing the US Site Visit International Site

Exploration of a novel HRD signature (HRDsig) as a biomarker of first line FOLFIRINOX benefit in metastatic pancreatic cancer

This abstract was presented at the 2022 European Society for Medical Oncology Congress. View the full abstract on esmo.org.

September 7, 2022